Kiniksa Pharmaceuticals's total assets for Q4 2024 were $580.55M, an increase of 4.55% from the previous quarter. KNSA total liabilities were $142.12M for the fiscal quarter, a 20.14% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.